Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 3/20 | 0.60 |
| ▸ | MINK1 | Q8N4C8 | 3/20 | 0.60 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.60 |
| ▸ | S1PR1 | P21453 | 17/20 | 0.60 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.57 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.56 |
| ▸ | MARK3 | P27448 | 1/20 | 0.56 |
| ▸ | PLK1 | P53350 | 1/20 | 0.56 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.56 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1964923 | 0.89 | S1PR1 (0.53) | MAP4K4MINK1PRKCDS1PR1S1PR3 | |
| SCHEMBL3741047 | 0.88 | S1PR1 (0.73) | MAP4K4MINK1PRKCDS1PR1S1PR3 | |
| SCHEMBL1969165 | 0.87 | S1PR1 (0.50) | MAP4K4MINK1PRKCDS1PR1S1PR3 | |
| SCHEMBL28656533 | 0.87 | S1PR1 (0.57) | MAP4K4MINK1S1PR1S1PR3S1PR5 | |
| SCHEMBL12582041 | 0.86 | MAP4K4 (0.45) | MAP4K4MINK1PRKCDS1PR1S1PR3 | |
| SCHEMBL3741171 | 0.85 | MAP4K4 (0.65) | MAP4K4MINK1PRKCDS1PR1S1PR3 | |
| SCHEMBL3743596 | 0.85 | MAP4K4 (0.60) | MAP4K4MINK1PRKCDS1PR1S1PR3 | |
| SCHEMBL1969626 | 0.85 | MAP4K4 (0.60) | MAP4K4MINK1PRKCDS1PR1S1PR3 | |
| SCHEMBL1969630 | 0.85 | MAP4K4 (0.60) | MAP4K4MINK1PRKCDS1PR1S1PR3 | |
| SCHEMBL1966428 | 0.84 | MAP4K4 (0.64) | MAP4K4MINK1PRKCDS1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7834039-B2 | Oxadiazole compounds | ABBOTT LABORATORIES (US) | 2010-11-16 | — | — | US | claimed |
| EP-2509424-A1 | NOVEL OXADIAZOLE COMPOUNDS | Abbott Laboratories (US) | 2012-10-17 | — | — | EP | disclosed |
| US-20110207704-A1 | Novel Oxadiazole Compounds | ABBOTT LABORATORIES (US) | 2011-08-25 | — | — | US | disclosed |
| US-20110207704-A1 | Novel Oxadiazole Compounds | ABBOTT LABORATORIES (US) | 2011-08-25 | — | — | US | disclosed |
| US-20110207704-A1 | Novel Oxadiazole Compounds | ABBOTT LABORATORIES (US) | 2011-08-25 | — | — | US | disclosed |
| WO-2011071570-A1 | NOVEL OXADIAZOLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-16 | — | — | WO | disclosed |
| WO-2011071570-A1 | NOVEL OXADIAZOLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-16 | — | — | WO | disclosed |
| US-7834039-B2 | Oxadiazole compounds | ABBOTT LABORATORIES (US) | 2010-11-16 | — | — | US | disclosed |
| US-7834039-B2 | Oxadiazole compounds | ABBOTT LABORATORIES (US) | 2010-11-16 | — | — | US | disclosed |
| US-7834039-B2 | Oxadiazole compounds | ABBOTT LABORATORIES (US) | 2010-11-16 | — | — | US | disclosed |
| EP-2109364-A1 | NOVEL OXADIAZOLE COMPOUNDS | Abbott Laboratories (US) | 2009-10-21 | — | — | EP | disclosed |
| US-20080280876-A1 | Novel oxadiazole compounds | ABBVIE INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080280876-A1 | Novel oxadiazole compounds | ABBVIE INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080280876-A1 | Novel oxadiazole compounds | ABBVIE INC. | 2008-11-13 | — | — | US | disclosed |
| WO-2008076356-A1 | NOVEL OXADIAZOLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008076356-A1 | NOVEL OXADIAZOLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207704-A1 | Novel Oxadiazole Compounds | S1PR3, S1PR1, S1PR2 | MAP4K4 2535/4885MINK1 1243/4885PRKCD 614/4885 |
| US-20080280876-A1 | Novel oxadiazole compounds | S1PR3, S1PR1, S1PR2 | MAP4K4 2535/4885MINK1 1243/4885PRKCD 614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.